Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Evidence in favor of adding docetaxel in treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has led to docetaxel in conjunction with androgen deprivation therapy (ADT) as standard therapy. The aim of this study was to examine the effectiveness of docetaxel with ADT for Korean patients with mHSPC in real-world practice. Materials and Methods: A retrospective cohort study was performed at six Korean hospitals for patients with mHSPC treated with docetaxel plus ADT. Patients were treated every 3 weeks for up to six cycles with 75 mg/m2 of docetaxel. The primary endpoint was time to castration resistant prostate cancer (CRPC). Results: This study included 46 eligible patients from June 2016 to February 2021. Median age was 68.5 years (range, 52–84) and all patients present with de novo M1 with high-volume disease. The median prostate-specific antigen (PSA) level at ADT initiation was 205.4 (7.7–1933) ng/mL, and time from ADT to docetaxel was 2.4 months (0–5.3). All six planned cycles of docetaxel were de livered in 36 patients (78%), 7 patients (15%) discontinued treatment due to adverse events, and 3 patients (7%) discontinued due to progression. At the time of the analysis, CRPC had developed in 34 patients (74%), and the median time to CRPC was 18.0 (95% con fidence interval, 14.1–21.9) months. PSA <0.2 ng/mL was achieved in 11 patients (24%) after 6 months of ADT and in 10 patients (22%) after 12 months. At last follow-up, 35 patients (76%) were alive; the median overall survival was not reached. Conclusion: The effect of docetaxel combined with ADT for Korean patients with mHSPC is comparable with prior results in West ern studies.
Abstract
Purpose: Evidence in favor of adding docetaxel in treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has led to docetaxel in conjunction with androgen deprivation therapy (ADT) as standard therapy. The aim of this study was to examine the effectiveness of docetaxel with ADT for Korean patients with mHSPC in real-world practice. Materials and Methods: A retrospective cohort study was performed at six Korean hospitals for patients with mHSPC treated with docetaxel plus ADT. Patients were treated every 3 weeks for up to six cycles with 75 mg/m2 of docetaxel. The primary endpoint was time to castration resistant prostate cancer (CRPC). Results: This study included 46 eligible patients from June 2016 to February 2021. Median age was 68.5 years (range, 52–84) and all patients present with de novo M1 with high-volume disease. The median prostate-specific antigen (PSA) level at ADT initiation was 205.4 (7.7–1933) ng/mL, and time from ADT to docetaxel was 2.4 months (0–5.3). All six planned cycles of docetaxel were de livered in 36 patients (78%), 7 patients (15%) discontinued treatment due to adverse events, and 3 patients (7%) discontinued due to progression. At the time of the analysis, CRPC had developed in 34 patients (74%), and the median time to CRPC was 18.0 (95% con fidence interval, 14.1–21.9) months. PSA <0.2 ng/mL was achieved in 11 patients (24%) after 6 months of ADT and in 10 patients (22%) after 12 months. At last follow-up, 35 patients (76%) were alive; the median overall survival was not reached. Conclusion: The effect of docetaxel combined with ADT for Korean patients with mHSPC is comparable with prior results in West ern studies.
참고문헌 (35)
- Prostate Cancer Trialists Collaborative Group, "Maximum androgen blockade in advanced prostate cancer : an overview of the randomised trials", Lancet, 355, pp.1491~1498 (2000)
- Lowrance WT, "Advanced prostate cancer : AUA", ASTRO, J Urol, pp.2021, 205[DOI]
- Gravis G, "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer(GETUG-AFU 15) : a randomised, openlabel, phase 3 trial", Lancet Oncol, 14, pp.149~158 (2013)
- Sweeney CJ, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer", N Engl J Med, 373, pp.737~746 (2015)
- James ND, "Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer(STAMPEDE) : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial", Lancet, 387, pp.1163~1177 (2016)
- Kyriakopoulos CE, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer : long-term survival analysis of the randomized phase III E3805 CHAARTED trial", J Clin Oncol, 36, pp.1080~1087 (2018)
- Tucci M, "Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer : a systematic review and meta-analysis", Eur Urol, 69, pp.563~573 (2016)
- Gillessen S, "Management of patients with advanced prostate cancer : report of the advanced prostate cancer consensus conference 2019", Eur Urol, 77, pp.508~547 (2020)
- "Prostate Cancer (version 4. 2022)"[URL]
- Carioli G, "European cancer mortality predictions for the year 2020 with a focus on prostate cancer", Ann Oncol, 31, pp.650~658 (2020)
- Taguchi T, "Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug", Gan To Kagaku Ryoho, 21, pp.1997~2005 (1994)
- Tanaka N, "The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration : JMTO Pca 10-01 phase II trial", Jpn J Clin Oncol, 47, pp.247~251 (2017)
- 이재련, "Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea", Cancer Research and Treatment, 42(1), pp.12~17 (2010), 대한암학회
- Yoon SE, "A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer", BMC Urol, 19, pp.30~ (2019)
- Byeon S, "A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer", BMC Cancer, 21, pp.1281~ (2021)
- Fizazi K, "Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer(PEACE-1) : a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design", Lancet, 399, pp.1695~1707 (2022)
- Smith MR, "Darolutamide and survival in metastatic, hormone-sensitive prostate cancer", N Engl J Med, 386, pp.1132~1142 (2022)
- Lendorf ME, "Effectiveness of docetaxel for metastatic hormone-sensitive prostate cancer in clinical practice", Eur Urol Open Sci, 24, pp.25~33 (2021)
- Lavoie JM, "Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis", Prostate, 79, pp.281~287 (2019)
- Poon DMC, "Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer : the first real-life experience in Asia", Asia Pac J Clin Oncol, 14, pp.347~352 (2018)
- 권휘안, "Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study", Investigative and Clinical Urology, 60(3), pp.195~201 (2019), 대한비뇨의학회[DOI]
- Finianos A, "Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease", Clin Genitourin Cancer, 16, pp.85~89 (2018)
- Jeong IG, "Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men : a retrospective cohort study of radical prostatectomy", Urol Oncol, 34, pp.3~ (2016)
- Hussain M, "Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer : data from Southwest Oncology Group Trial 9346(INT-0162)", J Clin Oncol, 24, pp.3984~3990 (2006)
- Parker CC, "Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer(STAMPEDE) : a randomised controlled phase 3 trial", Lancet, 392, pp.2353~2366 (2018)
- Fizazi K, "Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer", N Engl J Med, 377, pp.352~360 (2017)
- James ND, "Abiraterone for prostate cancer not previously treated with hormone therapy", N Engl J Med, 377, pp.338~351 (2017)
- Vale CL, "What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis", Ann Oncol, 29, pp.1249~1257 (2018)
- Armstrong AJ, "ARCHES : a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer", J Clin Oncol, 37, pp.2974~2986 (2019)
- Chi KN, "Apalutamide for metastatic, castrationsensitive prostate cancer", N Engl J Med, 381, pp.13~24 (2019)
- Feyerabend S, "Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer : a network meta-analysis", Eur J Cancer, 103, pp.78~87 (2018)
- Sydes MR, "Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer : directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol", Ann Oncol, 29, pp.1235~1248 (2018)
- Morgans AK, "Quality of life during treatment with chemohormonal therapy : analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer", J Clin Oncol, 36, pp.1088~1095 (2018)
- Rush HL, "Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial", J Clin Oncol, 40, pp.825~836 (2022)
- Collette L, "Prostate specific antigen : a prognostic marker of survival in good prognosis metastatic prostate cancer?(EORTC 30892)", Eur Urol, 44, pp.182~189 (2003)